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Abstract
Neurofibromatosis type 1 (NF-1) is a com-
mon hereditary neuro-cutaneous disease, with
known gene mutations, that mainly involves
the skin and nervous system. Multiple sclero-
sis (MS) is an acquired inflammatory disease
in which the myelin of nerve cells in the brain
and spinal cord is damaged. These two disease
do not share any apparent pathological similar-
ities. We herein present a 32-year-old woman
with definite NF-1, who has recently been
diagnosed with MS, which to the best of our
knowledge is a rare co-occurrence. Though
there are often neurologic sign and symptoms
in patients with NF-1, they should not always
be considered as the natural history of the dis-
ease, and other overlapped pathologies should
be kept in mind, in order to not miss or post-
pone the efficient treatment.
Introduction
Neurofibromatosis (NF) is actually two sep-
arate disease that are clinically and genetically
distinct and carry a high risk of tumor forma-
tion, particularly in the brain.1 The neurologi-
cal sign and symptoms of NF-1 include mild
intellectual impairment, epilepsy, macro-
cephaly, vision loss resulting from visual path-
way gliomas, weakness, numbness,
bowel/bladder dysfunction due to spinal nerve
roots neurofibromas or schwannomas.2-4
Multiple sclerosis (MS) is the most common
inflammatory demyelinating disease of the
central nervous system (CNS). The most com-
mon sign and symptoms of MS consist of
vision loss, sensory disturbances, weakness,
bowel/bladder dysfunction, diplopia and
ataxia.5
Primary progressive multiple sclerosis
occurs with increased frequency in NF-1 and
relapsing remitting disease has also been
reported.6-8 Co-occurrence of MS and NF-1 is
therefore rare.9
We report a 32-year-old woman with definite
NF-1, presenting with upper limb weakness in
whom the previous history of self-limited cere-
bellar attack and neuroimaging findings of
brain and spinal cord are compatible with
relapsing remitting MS. 
Case Report
A 32-year-old Iranian woman, known case of
NF-1, was admitted to Rasoul-Akram Hospital,
affiliated to Iran University of Medical Science,
with weakness of right arm and distal pares-
thesia of both hands since the previous week.
She did not have lower limbs weakness nor
visual or sphincter problem. Her past history
was remarkable for a self-limited binocular
diplopia with no eye pain, congestion or visual
loss and a history of vertigo accompanied with
imbalance, five months and two weeks prior to
her admission respectively. The past drug his-
tory was negative. Her family history was
remarkable for her mother and three sisters
suffering from NF-1. The physical examination
of skin revealed diffuse cafe-au-lait spots in
variable sizes, axillary freckling and multiple
subcutaneous neurofibromas (Figure 1).  Her
mental state was normal.  The motor force of
right arm was 4/5 with normal sensation and
generalized hyperreflexia was detected. Other
neurologic examination including cranial
nerves, fundoscopic exam and motor and sen-
sory systems of other limbs were entirely nor-
mal. Magnetic resonance imaging (MRI) of the
cervical spinal cord, with and without gadolin-
ium (GD), was performed showing an intra-
axial hypersignal lesion with enhancement
(Figure 2). In addition, brain MRI, with and
without GD revealed multiple hypersignal
lesions in T2-weighted and fluid attenuated
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Figure 1. Multiple cafe-au-lait spots and
cutaneous neurofibroma.
Figure 2. T2/W cervical magnetic reso-
nance imaging showing a hypersignal
intramedullary demyelinating plaque (A,
red arrow), with enhancement on T1 with
gadolinium (B).
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inversion recovery (FLAIR) sequences in
periventricular and juxtacortical white matter
and cerebellum with enhancement (Figure 3),
which all were compatible with demyelinating
plaques in MS and obviously distinct from non-
enhancing unidentified bright objects occa-
sionally seen symmetrically in the basal gan-
glia, brain stem and cerebellum in NF-1.3 Brain
MRI also showed an asymptomatic large extra-
axial avidly enhancing lesion at left side of the
neck probably an intracranial neurofibroma or
shwannoma (Figure 4); however, no biopsy
was performed. Infectious etiologies such as
varicella zoster virus, herpes simplex virus
and cytomegalovirus were tested by poly-
merase chain reaction (PCR) in cerebrospinal
fluid (CSF) and all were negative. Oligoclonal
bands (OCB) was positive in CSF and visual
evoked potential was normal bilaterally. The
patient symptoms improved significantly with
methylprednisolone pulse therapy with total
dose of 5 grams.
Discussion
The association of MS with NF-1 is unusual
and rarely has been reported in literature.6,10
Only twenty cases of co-occurrence of NF-1 and
MS have been written down so far,6-8,11-15
among which seven cases were reported from
Iran introduced by Etemadifar et al. in 2009.9
According to the available data, all clinical
forms of MS can be found in patients with NF-
1.6 In this report we describe a 32-year-old
woman with NF-1 presenting with motor symp-
toms and history of self-limited cerebellar
impairment. Typical demyelinating enhancing
plaques on brain and cervical cord MRI with
positive OCB and excluding other common
causes, confirmed the diagnosis of multiple
sclerosis. This association is particularly inter-
esting because the gene for oligodendrocyte
myelin glycoprotein (OMgp), a membrane gly-
coprotein found in central nervous system dur-
ing myelination, might be one of the possible
target antigens of the autoimmune attack in
demyelinating diseases and embedded within
intron 27b of the NF-1 gene, located on chro-
mosome 17q11.2 and a single mutation in the
OMgp gene may occur in patients with MS.16,17
Conclusions
Reporting another case of co-occurrence of
MS and NF-1, we intended to strengthen the
possible causal relationship between MS as an
acquired inflammatory demyelinating disease
and NF-1 as a hereditary disease, indicating
higher risk of MS incidence among patients
suffering from NF-1 and not to counting on all
new neurologic findings as the natural history
of NF-1 involving central or peripheral nervous
system, so take a holistic review of patient pre-
senting with a new neurologic complaint.
                             Case Report
[page 26]                                                         [Neurology International 2015; 7:5966]
Figure 3. T2/W brain magnetic resonance imaging showing multiple hypersignal plaques in cerebellum, pons and periventricular cere-
bral white matter (first 5 panels), with enhancing on T1/W sequences with gadolinium (last panel).
Figure 4. T1/W sequence with and without gadolinium showing an extra-axial lesion at left jugular foramina with avid enhancement.
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